title: Hepatitis C therapeutics: current status and emerging strategies.
abstract: Chronic infection with hepatitis C virus (HCV) is an emerging global epidemic. The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus. Despite these obstacles, inhibitors of the replicative elements of HCV, immune modulators and non-specific hepatoprotective agents are being pursued and exciting progress has been made. Successful therapeutic intervention of HCV will probably require combination approaches and new approaches, including host drug discovery targets.
authors.affiliation: Infectious Diseases Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
authors.forename: Seng-Lai
authors.initials: SL
authors.lastname: Tan
authors.forename: Arnim
authors.initials: A
authors.lastname: Pause
authors.forename: Yuguang
authors.initials: Y
authors.lastname: Shi
authors.forename: Nahum
authors.initials: N
authors.lastname: Sonenberg
mesh_terms: D000818:Animals; D001483:Base Sequence; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008969:Molecular Sequence Data; D013678:Technology, Pharmaceutical / Q000379:methods*; D014761:Viral Hepatitis Vaccines / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D014761:Viral Hepatitis Vaccines